Valeant Pharmaceuticals International, Inc. Form 4 January 04, 2016

January 04, 2	.016											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB APPROVAL				
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Expires: Estimated a burden hou response n	irs per			
(Print or Type R	lesponses)											
INGRAM ROBERT ALEXANDER Symbol			Symbol	2. Issuer Name <b>and</b> Ticker or Trading Symbol Valeant Pharmaceuticals					5. Relationship of Reporting Person(s) to Issuer			
				ernational, Inc. [VRX]					(Check all applicable)			
(Last) 2150 ST. EL	(First)	(Middle) . WEST	3. Date of (Month/Da 12/31/20	ay/Year)		nsaction			X Director Officer (give below)		6 Owner er (specify	
			Amendment, Date Original d(Month/Day/Year)					<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>X_ Form filed by One Reporting Person</li> </ul>				
LAVAL, A8	8 H7L 4A8								Form filed by M Person	Iore than One Ro	eporting	
(City)	(State)	(Zip)	Table	e I - Non	-De	rivative S	ecuri	ties Ac	quired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction I (Month/Day/Ye	ar) Executi any	emed on Date, if /Day/Year)	Code (Instr. 3	8)	4. Securit nAcquired Disposed (Instr. 3, Amount	(A) o of (D	)	Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, no	12/31/2015			А		239 (1)	A	\$ 0	68.866	D		
Stock, no	12/31/2015			А		239 <u>(1)</u>	А	\$0	68,866	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

par value

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
INGRAM ROBERT ALEXANDER 2150 ST. ELZEAR BLVD. WEST LAVAL, A8 H7L 4A8	Х						
Signatures							
by: Nicholas Zanoni for Robert Ingram	01	1/04/2016					
**Signature of Reporting Person		Date					

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Quarterly grant of Restricted Share Units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.